SUNESIS PHARMACEUTICALS INC 4
4 · SUNESIS PHARMACEUTICALS INC · Filed Dec 21, 2015
Insider Transaction Report
Form 4
Misfeldt Dayton
Director10% Owner
Transactions
- Purchase
Common Stock
2015-12-21$0.84/sh+32,725$27,489→ 137,859 total(indirect: See footnotes.) - Purchase
Common Stock
2015-12-21$0.84/sh+1,717,275$1,442,511→ 7,234,441 total(indirect: See footnotes.)
Holdings
- 1,515(indirect: See footnote.)
Common Stock
Footnotes (4)
- [F1]The reporting person is a Managing Director of Bay City Capital LLC, a Delaware limited liability company ("BCC"). BCC is the manager of Bay City Capital Management V LLC, a Delaware limited liability company ("Management V"). Management V is the general partner of Bay City Capital Fund V, L.P., a Delaware limited partnership ("Fund V") and Bay City Capital Fund V Co-Investment Fund, L.P., a Delaware limited partnership ("Co-Investment V") and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. BCC, the manager of Management V, is also an advisor to Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held. Mr. Misfeldt, BCC and Management V disclaim beneficial ownership with respect to the securities reported in this Form 4, except to the extent of their pecuniary interest therein.
- [F2]The securities are held by Fund V.
- [F3]The securities are held by Co-Investment V.
- [F4]The securities are held by BCC.